Rosen Quoted on Obstacles to Generic EpiPen

24 October 2016 Reuter’s Westlaw News

Reuter’s Westlaw

Partner David Rosen participated in a question and answer session with Reuter’s Westlaw, “Q&A: Foley & Lardner’s David Rosen on Obstacles to Generic EpiPen,” on October 24, 2106. The article discussed obstacles to getting a generic version of Mylan’s EpiPen on the market and how the U.S. Food and Drug Administration (FDA) can hasten the process.

In response to whether or not the FDA can help generic products reach the market, Rosen said, “They could facilitate them by having a little bit more interaction with the applicants, i.e., allowing them to come in for a meeting so they can address the issues and concerns with the developmental process and so they can understand FDA’s expectations. That will also help FDA understand and appreciate the developmental work that’s being done. Companies can get a little more guidance on what they’re doing and how they can meet FDA’s expectations for approval.”

Related Services


A Review of Recent Whistleblower Developments
19 July 2019
Legal News: Whistleblower Developments
Blockchain: A Tool With a Future in Healthcare
18 July 2019
Health Care Law Today
Do You Know What IMMEX Stands For?
16 July 2019
Dashboard Insights
Does The U.S. Need STRONGER Patents?
16 July 2019
PTAB Trial Insights
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
MAGI’s Clinical Research Conference
29 October 2019
Las Vegas, NV
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ